Novavax COVID-19 Vaccine, Adjuvanted

On August 27, 2025, the Food and Drug Administration revoked the Emergency Use Authorization (EUA) for Novavax COVID-19 Vaccine, Adjuvanted. Nuvaxovid (COVID-19 Vaccine, Adjuvanted), manufactured for Novavax Inc., is approved for use by FDA.

Fact Sheets (English)

Information	Last Updated
Fact Sheet for Healthcare Providers Administering Vaccine	August 30, 2024
Fact Sheet for Recipients and Caregivers	August 30, 2024

Regulatory Information (Emergency Use Authorization)

Information	Date
Revocation Letter	August 27, 2025
Revocation Memorandum	August 27, 2025
Letter of Authorization (Reissued)	August 30, 2024
Decision Memo - Novavax COVID-19 Vaccine, Adjuvanted	August 30, 2024
Advisory Committee Meeting Information	June 7, 2022

Federal Register Notices

Title	Date
Authorization of Emergency Use of a Biological Product During the COVID-19 Pandemic; Availability	August 29, 2022

Translations of the Fact Sheet for Recipients and Caregivers
 

受种人和照护者情况说明书 (August, 2024)	中文 (Chinese, Simplified)
접종자와 보호자를 위한 팩트 시트 (August, 2024)	한국어 (Korean)
HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES AUTORIZACIÓN DE USO DE EMERGENCIA (EUA) DE LA VACUNA CONTRA EL COVID-19 DE NOVAVAX CON ADYUVANTE (FÓRMULA 2024 – 2025) PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) EN PERSONAS DE 12 AÑOS O MAYORES (August, 2024)	Español (Spanish)
FACT SHEET PARA SA MGA TATANGGAP AT TAGAPAG-ALAGA (August, 2024)	Tagalog (Tagalog)
TỜ THÔNG TIN DÀNH CHO NGƯỜI NHẬN VÀ NGƯỜI CHĂM SÓC (August, 2024)	Tiếng Việt (Vietnamese)